AWS Launches Amazon Bio Discovery to Accelerate Drug Design

Amazon Web Services has launched Amazon Bio Discovery, a new AI-powered application designed to help scientists accelerate drug discovery by combining machine learning models with real-world lab testing. The platform introduces a “lab-in-the-loop” workflow, where AI-generated drug candidates are tested experimentally and fed back into the system to improve future results.

The application provides access to a broad catalog of biological foundation models, or bioFMs, trained on large biological datasets. These models can generate and evaluate potential drug candidates, particularly antibodies, during early-stage research. Scientists interact with the system through an AI agent that helps design experiments, select appropriate models, and optimize inputs using natural language rather than code.

Amazon Bio Discovery is designed to lower barriers to AI adoption in life sciences. Traditionally, using advanced models required specialized computational expertise and infrastructure. The new platform simplifies this process by offering pre-benchmarked models, automated workflows, and integrated tools for comparing performance. Researchers can also fine-tune models using their own experimental data without building custom pipelines, keeping proprietary data secure within their organization.

Closing the Loop Between AI and the Lab

A key feature of the platform is its integration with laboratory partners, including Twist Bioscience and Ginkgo Bioworks. Scientists can send AI-generated candidates directly for synthesis and testing, with results automatically routed back into the system. This creates a continuous feedback loop, allowing each experiment to improve the next iteration.

The approach has already shown early results. In collaboration with Memorial Sloan Kettering Cancer Center, researchers used the platform to design hundreds of thousands of antibody candidates for pediatric cancer therapies. What traditionally takes months or even a year was reduced to a matter of weeks, from initial design to lab testing.

Democratizing AI in Life Sciences

Amazon Bio Discovery reflects a broader push to make advanced AI tools accessible to a wider range of scientists, not just those with machine learning expertise. By combining model access, experiment design, and lab coordination into a single platform, AWS aims to streamline workflows that are often fragmented across multiple systems and teams.

The platform is built on infrastructure already widely used in the pharmaceutical industry, with AWS noting that 19 of the top 20 global drugmakers rely on its cloud services. Early adopters include Bayer, the Broad Institute, and Fred Hutch Cancer Center. The launch also aligns with a wider wave of AI-driven partnerships across the sector, such as Novo Nordisk teaming up with OpenAI to accelerate drug discovery for obesity and diabetes treatments.

As AI becomes more embedded in drug development, platforms like Amazon Bio Discovery highlight a shift toward integrated systems that connect computational design with real-world experimentation. This convergence could significantly shorten development timelines and expand access to advanced research tools across the life sciences ecosystem.

AI & Machine Learning, News, Research & Innovation